- Home
- BORR vs PCRX Comparison
BORR vs PCRX Comparison
Compare BORR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BORR | PCRX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.1M | 1.0B |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BORR | PCRX |
|---|---|---|
| Price | $4.31 | $25.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.75 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 5.2M | 637.6K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.28 | ★ 0.47 |
| Revenue | ★ $1,024,500,000.00 | $716,791,000.00 |
| Revenue This Year | $1.03 | $6.24 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | ★ $15.57 | $52.56 |
| Revenue Growth | ★ 5.83 | 3.14 |
| 52 Week Low | $1.55 | $18.17 |
| 52 Week High | $4.48 | $27.64 |
Technical Indicators
Market Signals| Indicator | BORR | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 77.46 | 64.93 |
| Support Level | $3.25 | $23.63 |
| Resistance Level | $3.34 | $24.81 |
| Average True Range (ATR) | 0.22 | 0.99 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 88.99 | 93.40 |
Price Performance
Historical ComparisonAbout BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.